| Typ : |
Labor |
|
| Forschungsgruppen : |
|
| Autoren : |
|
| Titel : |
Atezolizumab (Tecentriq®) - Summary of Product Characteristics |
| Veröffentlichung : |
Roche Products Limited 2021 |
|
| Niveau von Beweisen : |
|
| physikalische Stabilität : |
|
| chemische Stabilität : |
|
| andere Verfahren : |
|
| Kommentare : |
|
Molekülverzeichnis
 Atezolizumab
|
 |
 |
 |
 |
3.2 >> 16.8 mg/ml |
2-8°C |
 |
| 30 |
 |
|
|
|
|
|
3.2 >> 16.8 mg/ml |
<30°C |
|
| 24 |
 |
|
|
|
 |
|
3.2 >> 16.8 mg/ml |
2-8°C |
|
| 30 |
|
|
|
|
|
|
3.2 >> 16.8 mg/ml |
<30°C |
|
| 24 |
|
|
|
|
 |
|
3.2 >> 16.8 mg/ml |
2-8°C |
|
| 30 |
|
|
|
|
|
|
3.2 >> 16.8 mg/ml |
<30°C |
|
| 24 |
|
|
|
|
 |
|
3.2 >> 16.8 mg/ml |
2-8°C |
|
| 30 |
|
|
|
|
|
|
3.2 >> 16.8 mg/ml |
<30°C |
|
| 24 |
|
|
|
|
|
| |
+
|
|
|
|
